Want to see RNA full AI Analyst Report?
RNA Stock Chart & Stats
$13.64
-$0.39(-1.27%)
At close: 4:00 PM EST
$13.64
-$0.39(-1.27%)
Day’s Range― - ―
52-Week Range$9.50 - $16.77
Previous CloseN/A
Volume185.29K
Average Volume (3M)234.65K
Market Cap
$174.65M
Enterprise Value-$32.45
Total Cash (Recent Filing)$264.21M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,105,642
10 Day Avg. Volume396,054
30 Day Avg. Volume234,645
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)13.56
P/FCF Ratio-5.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.00Price Target Upside83.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage reduces refinancing and solvency pressure, giving the company greater flexibility while it funds development. This limits fixed financial obligations and may help preserve strategic options during continued operating losses, although it does not resolve the underlying cash burn.
Exceptional Gross MarginGross margins near 98–100% indicate that reported revenue carries substantial contribution after direct costs. If revenue scales, this structure could support meaningful operating leverage; however, the benefit remains unrealized while operating expenses and investment keep the company deeply unprofitable.
Losses Improved From 2024 ExtremesImprovement from the extreme loss levels recorded in 2024 suggests some progress in financial performance and may indicate that losses are becoming less severe. Sustaining that direction would improve funding needs over time, though current losses remain large and the business is not yet self-financing.
Bears Say
Persistent Cash BurnHeavy and persistent cash burn means the company is consuming substantial resources to operate and remains reliant on external funding. This can weaken financial flexibility, increase dilution or financing needs, and make continued development dependent on maintaining access to capital.
Small, Volatile Revenue BaseA small and volatile revenue base provides limited evidence of durable commercial scale and leaves the company with little operating support for its cost structure. The recent decline further raises concern that revenue may not yet be expanding fast enough to absorb ongoing investment.
Deep Ongoing UnprofitabilityLarge net and operating losses materially constrain internal funding and keep the business dependent on cash reserves or external capital. Until operating losses narrow substantially, the company has limited capacity to reinvest from earnings and remains exposed to prolonged execution and financing pressure.
Atrium Therapeutics, Inc. News
RNA FAQ
What was Atrium Therapeutics, Inc.’s price range in the past 12 months?
Atrium Therapeutics, Inc. lowest stock price was $9.50 and its highest was $16.77 in the past 12 months.
What is Atrium Therapeutics, Inc.’s market cap?
Atrium Therapeutics, Inc.’s market cap is $174.65M.
When is Atrium Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atrium Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Atrium Therapeutics, Inc. overvalued?
According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Undervalued.
Does Atrium Therapeutics, Inc. pay dividends?
Atrium Therapeutics, Inc. does not currently pay dividends.
What is Atrium Therapeutics, Inc.’s EPS estimate?
Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrium Therapeutics, Inc. have?
Atrium Therapeutics, Inc. has 17,105,642 shares outstanding.
What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atrium Therapeutics, Inc. Stock Smart Score
Company Description
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA Stock 12 Month Forecast
Average Price Target
$25.00
▲(83.28% Upside)
Technical Analysis
Arcturus Therapeutics
―
Rocket Pharmaceuticals
―
Cartesian Therapeutics
―
Precision BioSciences
―
Entrada Therapeutics Inc
―
Ownership Overview
2.24% Insiders
1.51% Mutual Funds
37.04% Other Institutional Investors
49.84% Public Companies and
Individual Investors